MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3346/jkms.2025.40.e127

Медицинская библиотека · Journal of Korean medical science · 2025

Calcitonin Gene-Related Peptide Monoclonal Antibody Treatment in Nine Cases of Persistent Headache Following COVID-19-Infection.

Choi Soyoun, Hong Yooha, Kang Mi-Kyoung, Song Tae-Jin, Cho Soo-Jin

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The coronavirus disease 2019 (COVID-19) pandemic has underscored the need for effective treatment for post-infectious complications, including headaches. Owing to the variable nature of post-COVID headaches, identifying effective therapies through clinical trials is challenging and the burden on patients is often severe. This study aimed to summarize the presentation of post-COVID headache in clinical practice and evaluate its response to treatment with calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs).

METHODS

In this retrospective cohort study, medical records obtained between March 2022 and May 2024 from two centers were analyzed. The study included nine patients with new-onset or significantly worsening or altered patterns of previous headaches lasting more than one month after COVID-19 infection who subsequently received CGRP mAbs. Demographics, headache frequency and severity, medication use, and quality of life were assessed before and after CGRP mAb treatment.

RESULTS

All patients were female (median age, 48 years), and 88.9% had headaches for more than three months despite conventional preventive therapies. Headache Impact Test-6 (HIT-6) scores were greater than 60 in all patients, and the headaches were unilateral (66.7%) and pulsating (22.2%). After CGRP mAb treatment, the monthly headache days, headache severity scores, and monthly medication days decreased significantly (median with interquartile range: 25 [15-28] to 5 [4-10], P = 0.012; 8 [7-9] to 3 [2-4], P = 0.011; 16 [15-20] to 5 [4-10], P = 0.017). The HIT-6 (65 [60-68] to 48 [48-60], P = 0.017) and Patient Health Questionnaire-9 scores (14 [5-15] to 10 [4-12], P = 0.028) also decreased significantly after treatment.

CONCLUSION

CGRP mAbs may be considered a potential treatment option for persistent headaches following COVID-19, especially the long-COVID headaches. Their use may contribute to an improved burden of headache and quality of life and may help alleviate the psychological symptoms associated with persistent headaches.

Для цитирования: Choi Soyoun, Hong Yooha, Kang Mi-Kyoung, Song Tae-Jin, Cho Soo-Jin. Calcitonin Gene-Related Peptide Monoclonal Antibody Treatment in Nine Cases of Persistent Headache Following COVID-19-Infection.. Journal of Korean medical science. 2025. DOI: 10.3346/jkms.2025.40.e127.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.